Analysis of the TCR and BCR repertoires revealed considerable heterogeneity both among patients and between pre- and post-PD-1 inhibitor treatment tumor specimens from the same patient (Fig. 1 B and C), suggesting a level of variability in the tumor-infiltrating lymphocyte population. This evidence concerns the gene BCR and neoplasm.